Biopharma sees tougher FDA approval process

The Wall Street Journal offers more bleak assessments from the pharma industry on their ability to win an FDA approval for a new therapy. Schering-Plough has already shuttered two programs it once held high hopes for and it may soon axe a third. Delays on prasugrel and Cordaptive are adding to the uncertainty and tomorrow an FDA panel will ponder tougher approval standards for diabetes drugs.

"What will it take to get new drugs approved?" Schering-Plough CEO Fred Hassan asks. "The point is, we don't know."

The WSJ notes that it's getting tougher to win an FDA approval even as the number of NDAs is already scraping a 24-year low.

- read the report from the Wall Street Journal

ALSO: Developers say FDA may force higher costs, more time for diabetes programs. Article

Suggested Articles

Janssen’s BCMA-targeting CAR-T therapy eliminated tumors in 69% of patients with advanced multiple myeloma in a small phase 1 study.

In a study, BMS' CAR-T therapy banished tumors in more than half and shrank tumors in nearly three-quarters of relapsed blood cancer patients.

Novartis unveiled more data showing how its asthma combo QMF149 fared against the standard of care: a combination of the same types of drugs.